ProfileGDS5678 / 1440341_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 56% 61% 61% 62% 62% 59% 62% 68% 63% 62% 61% 61% 60% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.463756
GSM967853U87-EV human glioblastoma xenograft - Control 23.6245261
GSM967854U87-EV human glioblastoma xenograft - Control 33.6389761
GSM967855U87-EV human glioblastoma xenograft - Control 43.6993362
GSM967856U87-EV human glioblastoma xenograft - Control 53.6498762
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.609259
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7656862
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1676568
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7395463
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6886162
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6179361
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6253361
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6273860
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6261961